Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. SEC filings document the company's commercial rare-disease business, including ORLADEYO® results, revenue guidance, pricing disclosures, and financial results furnished on Form 8-K. The filings also describe pipeline and business-development matters involving HAE programs, including navenibart licensing and the completed acquisition of Astria Therapeutics as a BioCryst subsidiary.
BioCryst's filings further cover financing and capital-structure matters, including term-loan arrangements, as well as proxy disclosures on board elections, executive compensation, equity awards, committee structure, and shareholder voting matters. Material-event reports and proxy statements provide the formal record for governance changes, strategic transactions, and Regulation FD disclosures.
BioCryst Pharmaceuticals plans to acquire Astria Therapeutics in a cash-and-stock merger that will make Astria a wholly owned subsidiary. Each share of Astria common stock will be converted into 0.59 of a share of BioCryst common stock plus $8.55 in cash, subject to a cap that limits new BioCryst shares issued in the deal to 19.9% of its pre‑merger shares, with cash increased if the share portion is reduced. Based on recent BioCryst trading prices, this implied about $12.70–$12.76 of value per Astria share around the announcement and mailing dates. Astria’s board unanimously determined the merger is fair and in stockholders’ best interests, obtained a fairness opinion from Evercore, and recommends voting in favor at a January 21, 2026 special meeting. Certain directors, executives and key holders have signed voting agreements supporting the transaction, and BioCryst has arranged a $550 million credit facility to help fund the cash portion.
BioCryst Pharmaceuticals reported an insider equity transaction by an officer serving as President and CCO. On 12/12/2025, 8,181 shares of common stock were withheld by the company at $7.57 per share to cover required tax withholding tied to the vesting of previously granted restricted stock units.
The explanation clarifies that this withholding is for tax purposes and does not represent a sale by the officer. Following this transaction, the officer directly beneficially owns 418,827 shares of BioCryst Pharmaceuticals common stock.
BioCryst Pharmaceuticals Chief Legal Officer Alane P. Barnes reported two equity transactions in December 2025. On December 12, 8,540 shares of common stock were withheld at $7.57 per share to satisfy required tax withholding tied to vesting restricted stock units, and this is explicitly described as not representing a sale by Barnes.
On December 15, Barnes sold 21,210 shares of common stock at $7.65 per share under a trading plan adopted on August 13, 2025 in accordance with Rule 10b5-1, with the transaction occurring automatically rather than as a discretionary trade. Following these transactions, Barnes directly beneficially owned 315,726 shares of BioCryst common stock.
BioCryst Pharmaceuticals reported that a director who also serves as Chief Executive Officer had 27,368 shares of common stock withheld on December 12, 2025 to satisfy required tax withholding obligations tied to the vesting of previously granted restricted stock units at a price of $7.57 per share.
After this transaction, the insider beneficially owns 1,405,222 shares directly, plus 30,000 shares held in each of two irrevocable trusts for which the insider’s spouse serves as co‑trustee.
The company notes that this tax withholding does not represent an open‑market sale by the reporting person.
BioCryst Pharmaceuticals reports that the U.S. Food and Drug Administration has approved its new drug application for an oral pellet formulation of once-daily ORLADEYO (berotralstat). The approval covers use of this oral pellet formulation as prophylactic therapy in pediatric patients with hereditary angioedema aged 2 to <12 years.
The company has furnished a press release with additional details about this FDA approval as an exhibit to this report.
BioCryst Pharmaceuticals, Inc. (BCRX) reported an insider share sale by a director. On 11/13/2025, the reporting person sold 9,600 shares of common stock at $7.14 per share in an open market sale, coded "S" for sale. After this transaction, the director beneficially owned 30,642 shares of BioCryst common stock in direct ownership form.
The shares were sold under a pre-arranged trading plan adopted on August 14, 2025 pursuant to Rule 10b5-1. This means the sale occurred automatically according to the plan’s terms rather than as a new discretionary trading decision by the director.
BioCryst Pharmaceuticals (BCRX) reported Q3 2025 results. Revenue was $159.4 million, up from $117.1 million a year ago, driven mainly by product sales of $157.7 million. Net income reached $12.9 million versus a prior-year loss, equal to $0.06 per diluted share. Year-to-date revenue was $468.3 million with net income of $18.0 million.
Operating cash flow for the nine months was $55.4 million. The company ended the quarter with cash and cash equivalents of $84.1 million, short‑term investments of $128.8 million, and long‑term investments of $39.7 million. On the balance sheet, the secured term loan declined to $194.4 million, and royalty financing obligations were $476.8 million in total. Assets and liabilities classified as held for sale were $29.2 million and $26.4 million, respectively.
BioCryst highlighted continued commercialization of ORLADEYO for HAE prevention, with U.S. distribution concentrated through a single specialty pharmacy. Management stated that financial resources as of September 30, 2025 are expected to fund operations for at least the next 12 months. Shares outstanding were 210.5 million as of October 31, 2025.
BioCryst Pharmaceuticals furnished a press release announcing recent corporate developments and financial results for the third quarter ended September 30, 2025. The company also referenced a conference call and webcast to discuss these updates.
The press release is attached as Exhibit 99.1. The information was furnished, not filed, which means it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.
BioCryst Pharmaceuticals (BCRX) agreed to acquire Astria Therapeutics via a cash-and-stock merger. Each Astria share will be exchanged for $8.55 in cash plus 0.59 of a BioCryst common share, with a cap that limits total new BioCryst shares to 19.9% of pre-close shares; if that cap is reached, the share portion decreases and the cash portion increases by the same value.
Closing is subject to Astria stockholder approval, HSR clearance, SEC effectiveness of a Form S-4 registering the BioCryst shares, Nasdaq listing approval for the new shares, and other customary conditions. The companies anticipate closing in the first quarter of 2026. Under specified circumstances, Astria would owe BioCryst a $32,250,000 termination fee.
BioCryst obtained a $550,000,000 senior secured debt commitment from Blackstone, including a $350,000,000 initial term loan and a $50,000,000 committed delayed draw, to help fund the consideration and related fees at closing. BioCryst also fully repaid and terminated its prior BioPharma Credit loan. Subject to the merger’s effective time, Astria CEO Jill C. Milne, Ph.D. is expected to join the BioCryst board, with an initial equity grant valued at $500,000.
BioCryst Pharmaceuticals, Inc. filed a Form 8-K reporting the consummation of a Transaction and furnishing a set of related agreements dated October 1, 2025. The filing lists six exhibits between the company and BioCryst Ireland: an Amended and Restated IP Licence Agreement, a Supply Agreement, a Global Brand and Support Agreement, a Transition Services Agreement, a Trademark License Agreement, and a Press Release regarding the Transaction. The filing states that schedules and exhibits to those agreements were omitted from the public filing under Item 601(a)(5) of Regulation S-K and are available to the SEC on request.